Other targets, including TNF receptor superfamily member 17 (TNFRSF17), CD22, CD38, CD33, and C-type lectin domain containing 14A (CLEC14A), demonstrated consistent but lower targeting potential across cancers (Figure 7, Supplementary Table S1). This evidence concerns the gene CD22 and cancer.